![]() |
產(chǎn)地 | 進(jìn)口、國(guó)產(chǎn) |
品牌 | 上海莼試 |
保存條件 | Store at -20 °C |
貨號(hào) | CS11459 |
應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:100-500 ICC=1:100-500 IF=1:100-500 |
CAS編號(hào) | |
抗體名 | Anti-TCTN3/TECT3 |
克隆性 | |
靶點(diǎn) | 詳見說明書 |
適應(yīng)物種 | 詳見說明書 |
形態(tài) | 詳見說明書 |
宿主 | 詳見說明書 |
亞型 | IgG |
標(biāo)識(shí)物 | 詳見說明書 |
濃度 | 1mg/1ml% |
免疫原 | KLH conjugated synthetic peptide derived from human TCTN3/TECT3 |
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn):
1. 結(jié)構(gòu)蛋白家族3抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析;
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件;
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活;
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等;
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性;
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合;
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用;
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
產(chǎn)品訂購(gòu)信息:
英文名稱 Anti-TCTN3/TECT3
中文名稱 結(jié)構(gòu)蛋白家族3抗體品牌
別 名 C10orf61; Chromosome 10 open reading frame 61; DKFZP564D116; TCTN3; TECT3_HUMAN; Tectonic 3; Tectonic 3 precursor; Tectonic family member 3; Tectonic-3.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Cow, Rabbit, Sheep
產(chǎn)品類型 一抗
研究領(lǐng)域 細(xì)胞生物 細(xì)胞凋亡 生長(zhǎng)因子和激素
蛋白分子量 predicted molecular weight: 64kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human TCTN3/TECT3
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
結(jié)構(gòu)蛋白家族3抗體品牌 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:100-500 ICC=1:100-500 IF=1:100-500
(石蠟切片需做抗原修復(fù))
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Tect3 is a 607 amino acid single-pass type I membrane protein that belongs to the tectonic family and exists as four alternatively spliced isoforms. Tect3 interacts with MKS1 and may be involved in apoptosis regulation. The gene that encodes Tect3 contains approximately 31,560 bases and maps to human chromosome 10q24.1. Spanning nearly 135 million base pairs and encoding nearly 1,200 genes, chromosome 10 makes up approximately 4.5% of the human genome. Several protein-coding genes, including those that encode chemokines, cadherins, excision repair proteins, early growth response factors (Egrs) and fibroblast growth receptors (FGFRs), are located on chromosome 10. Defects in some of the genes that map to chromosome 10 are associated with Charcot-Marie Tooth disease, Jackson-Weiss syndrome, Usher syndrome, nonsyndromatic deafness, Wolman’s syndrome, Cowden syndrome, Cockayne syndrome, multiple endocrine neoplasia type 2 and porphyria. Tetrahydrobiopterin deficiency and a number of syndromes involving defective skull and facial bone fusion are also linked to chromosome 10.
Function : May be involved in apoptosis regulation.
Subunit : Part of the tectonic-like complex (also named B9 complex) (By similarity).
Subcellular Location : Membrane.
DISEASE : Defects in TCTN3 are the cause of orofaciodigital syndrome 4 (OFD4) [MIM:258860]. A form of orofaciodigital syndrome, a group of heterogeneous disorders characterized by malformations of the oral cavity, face and digits, and associated phenotypic abnormalities that lead to the delineation of various subtypes. OFD4 patients have tongue nodules, multiple frenulae, broad flat nose, hypertelorism, and short rib polydactyly with tibial dysplasia (Majewski syndrome). The presence of severe tibial aplasia differentiates OFD4 from OFD1. Additional features of cystic dysplastic kidneys and brain malformation, including occipital encephalocele, are observed in severely affected patients.
Defects in TCTN3 are the cause of Joubert syndrome 18 (JBTS18) [MIM:614815]. A form of Joubert syndrome, a disorder presenting with cerebellar ataxia, oculomotor apraxia, hypotonia, neonatal breathing abnormalities and psychomotor delay. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include retinal dystrophy and renal disease. JBTS18 patients have vermis agenesis and the molar tooth sign as well as severe kyphoscoliosis. Other features include intrauterine growth retardation, oral anomalies, micrognathism, polydactyly and camptodactyly, joint laxity, horseshoe kidney, and ventricular septal defect. Note=TCTN3-mutated fibroblasts from JBTS18 patients fail to respond to Shh agonists suggesting that at least some of the defects in affected individuals may be secondary to reduced Shh signaling (PubMed:22883145).
Similarity : Belongs to the tectonic family.
Database links : UniProtKB/Swiss-Prot: Q6NUS6.2
抗體的鑒定:
1)結(jié)構(gòu)蛋白家族3抗體品牌 抗體的效價(jià)鑒定:不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2)抗體的特異性鑒定:抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力??贵w的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3)抗體親和力:是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol??贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
Anti-TP II A/TOP2a/FITC 熒光素標(biāo)記DNA拓普西異構(gòu)酶ⅡA抗體IgGMulti-class antibodies規(guī)格: 0.2ml
SAP-1 (Synapse associated protein-I) peptide 突觸相關(guān)蛋白-1(多肽抗原)Multi-class antibodies規(guī)格: 0.5mg
酪氨酸激酶A抗體 Anti-TrK A 0.1ml
SLU7 英文名稱: SLU7蛋白抗體 0.2ml
EN2 英文名稱: 同源盒蛋白轉(zhuǎn)錄因子EN2抗體 0.1ml
Rhesus antibody Rh phospho-IRS1(Ser612) 磷酸化受體底物-1抗體 規(guī)格 0.1ml
SAP-1 (Synapse associated protein-I) peptide 突觸相關(guān)蛋白-1(多肽抗原)Multi-class antibodies規(guī)格: 0.5mg
anti-Rarres2/TIG2/FITC 熒光素標(biāo)記視黃酸受體應(yīng)答蛋白2抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Nociceptin receptor 孤菲肽受體(痛敏肽受體)(抗原)Multi-class antibodies規(guī)格: 0.5mg
信號(hào)轉(zhuǎn)導(dǎo)和轉(zhuǎn)錄激活因子2抗體 Anti-STAT2 0.2ml
S100A11 英文名稱: S100鈣結(jié)合蛋白A11抗體 0.1ml
EpCAM 英文名稱: 上皮特異性抗原抗體 0.1ml
Rhesus antibody Rh Phospho-MAP2 (Thr1620/1623) 磷酸化微管相關(guān)蛋白2抗體 規(guī)格 0.1ml
Nociceptin receptor 孤菲肽受體(痛敏肽受體)(抗原)Multi-class antibodies規(guī)格: 0.5mg
PAR-1 (Protease-activated receptors-1) 蛋白酶激活受體-1抗原Multi-class antibodies規(guī)格: 0.5mg
Anti-phospho-ATF2(Ser490/498) 磷酸化活化復(fù)制因子2抗體Multi-class antibodies規(guī)格: 0.1ml
Rhesus antibody Rh phospho-APG4B(Ser309) 磷酸化自噬相關(guān)蛋白4B抗體 規(guī)格 0.1ml
S100 A4 濃縮液 0.1ml 進(jìn)口分裝
UBE2E2 英文名稱: 泛素蛋白連接酶2E2抗體 0.2ml
DHRS4L2 英文名稱: 短鏈脫氫酶/還原酶家族4樣2蛋白抗體 0.2ml
Anti-phospho-ATF2(Ser490/498) 磷酸化活化復(fù)制因子2抗體Multi-class antibodies規(guī)格: 0.1ml
IL3 Protein Rat 重組大鼠 IL3 / ierleukin 3 蛋白 (His 標(biāo)簽)
II型膠原酶(含100mL酶解緩沖液) 10mL
HA Others H3N2 甲型 H3N2 (A/Perth/16/2009) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
TE-1人細(xì)胞 Human esophageal cancer cell line TE-1. RPMI-1640(GIBCO)+10%FBS
SV40轉(zhuǎn)化的非洲綠猴腎細(xì)胞;COS-1
人毛發(fā)干細(xì)胞(HHDPC)( 5×105 ) MLF, 小鼠淋巴成纖維細(xì)胞 Mouse
CM-H077人心室肌細(xì)胞完全培養(yǎng)基100mL
CGB5 Others Human 人 CGB5 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
人外根鞘細(xì)胞HHORSC
NCL-H548細(xì)胞,人*癌細(xì)胞 人癌細(xì)胞,MDA-MB-231細(xì)胞 巨噬細(xì)胞培養(yǎng)基MaM
大額牛腎細(xì)胞;BFR-K1
LAYN Others Human 人 Layilin 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
結(jié)構(gòu)蛋白家族3抗體品牌 IL3 Protein Rat 重組大鼠 IL3 / ierleukin 3 蛋白 (His 標(biāo)簽)
II型膠原酶(含100mL酶解緩沖液) 10mL
HA Others H3N2 甲型 H3N2 (A/Perth/16/2009) 血凝素 (Hemagglutinin / HA) 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
TE-1人細(xì)胞 Human esophageal cancer cell line TE-1. RPMI-1640(GIBCO)+10%FBS
SV40轉(zhuǎn)化的非洲綠猴腎細(xì)胞;COS-1
人毛發(fā)干細(xì)胞(HHDPC)( 5×105 ) MLF, 小鼠淋巴成纖維細(xì)胞 Mouse